Deadly fungus in US threatens lives as infection rates rise in These seven states
A deadly fungus that can rot human tissue is spreading fast across the US, and experts say it could get worse as the weather gets hotter. The fungus is called Aspergillus fumigatus. It spreads through the air and is almost impossible to avoid. The spores are so small that people breathe them in without knowing.
This fungus can cause a lung infection called aspergillosis. For people with weak immune systems, this can lead to organ failure and even death. People with cancer, asthma, or HIV are at higher risk.
Scientists say the fungus is spreading in parts of the US, especially in warm, wet states like Florida, Louisiana, Texas, Georgia, and California. Cities like New York, Houston, and Los Angeles are also at risk because of their large populations and old buildings, as per Daily Mail.
Aspergillosis is not a disease that doctors have to report in the US, so there's no official tracking. That makes it hard to know how many people are getting sick or dying from it.
Doctors say people with weak immune systems should avoid soil, gardening, and mold. They should wear masks in dusty areas and keep the air clean in their homes and hospitals. US hospitals are doing more mold checks and using stronger antifungal drugs.
The Aspergillus fungus also makes a poison called aflatoxin. This can cause cancer and damage to the lungs, liver, stomach, spleen, colon, and kidneys.
Also Read: What is Fusarium graminearum, the fungus that 2 Chinese nationals allegedly used to target US food security?
A scientist from the University of Manchester said that this fungus could change where plants grow and what infections people get in the next 50 years. He said hundreds of thousands of lives are at risk.
About 400,000 people develop a long-term lung infection called chronic pulmonary aspergillosis. A more dangerous form, called invasive aspergillosis, is less common but often deadly. It mainly affects people with weak immune systems and can spread to the brain, heart, and kidneys.
One study showed that only 59% of organ transplant patients lived for one year after getting invasive aspergillosis. Only 25% of stem cell transplant patients survived that long.
The World Health Organization says Aspergillus fumigatus is a top-priority fungal threat because it is becoming more resistant to drugs and kills so many people. The fungus grows well in warm, damp places. It can even survive in compost piles over 120°F.
Because of climate change, the human body is becoming a better place for this fungus to grow. A new study from the University of Manchester says if we keep using fossil fuels like we are now, the fungus could spread 75% more by 2100. This would put millions more people at risk, especially in the southern U.S.
Drugs called azoles are often used to treat fungal infections in people, but they are also used a lot in farming to protect crops. Experts say using these drugs too much on farms may be making the fungus resistant. That means the drugs don't work anymore, even in humans.
A study found azole-resistant Aspergillus fumigatus in farm soil in at least seven US states. Many of these fungi are already resistant to regular antifungal drugs. Scientists say mixing of different fungus types is making the problem worse, and it's already a big issue in US soil.
The World Health Organization is calling for fast action, better drugs, quicker tests, and more training for doctors and nurses. They also want drug companies to focus more on fungal diseases and test new treatments on children too.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
A shot of hope
New HIV medicine is powerful – but can everyone afford it? A new medicine called lenacapavir has just been approved in the US to help stop people from getting HIV, the virus that causes AIDS. That's big news! Even though fewer people are getting HIV today than in the 1990s, around 13 lakh (1.3 million) people still get infected every year around the world. Lenacapavir is special because you only need two shots a year – not a pill every day like older medicines. That's great for people who forget daily pills or feel embarrassed taking them. And it's almost 100% effective at stopping HIV in adults and teens. But there's a big problem: the cost. In the US, it sells for over ₹23 lakh a year! Even rich countries find that hard to afford. The company that makes it, Gilead, is working with more than 100 poorer countries to help them make cheaper versions. Still, many African countries where HIV is most common may struggle to get it to the people who need it most. Scientists have been trying to create a proper HIV vaccine for decades, but HIV keeps mutating – changing too fast for one shot to work. New mRNA vaccines (like the ones used for Covid) are being tested, but funding cuts in the US have slowed down this research. That's why lenacapavir gives us hope. But hope only works if everyone, everywhere, can afford it. Facebook Twitter Linkedin Email Disclaimer Views expressed above are the author's own.
Time of India
2 hours ago
- Time of India
Dose of hope
Times of India's Edit Page team comprises senior journalists with wide-ranging interests who debate and opine on the news and issues of the day. To really help, new HIV vax has to be made cheap A pill to treat multidrug-resistant HIV, lenacapavir, has been approved by US drug regulator FDA as a preventive vaccine. This is a huge deal – incidence of HIV may have declined since 1990s but even today about 13L people globally are infected by the virus every year. But its price is an obstacle. Sold for $28,218 per year in US, it's prohibitive even for high-income nations. Pharma company Gilead that manufactures lenacapavir has reportedly tied up with over 100 middle- and low-income countries for manufacture of generics pending approvals. But access likely will still be tricky for poorer African countries that bear the HIV burden. Drugs to prevent HIV transmission have been around almost a decade, but a daily dosage regimen makes these unreliable. People forget and there's the stigma/doubt in partners that a daily dose is preventive. Lenacapavir needs to be taken just twice a year. Its long-lasting effect in preventing infection – almost 100% in adults and adolescents – is thus the best bet today. Also because HIV research in US bears the additional burden of Trump administration's slashed funds. An effective vaccine for HIV has been elusive for decades because of its rapid mutations. Several mRNA vaccines, like those developed for Covid and considered the most promising, are in clinical trials. But since Jan, under Trump's health secretary Bob Kennedy Jr, NIH stopped funding hundreds of such HIV vaccine-related research. This is what makes repurposed lenacapavir a lifeline, provided it's made affordable. Facebook Twitter Linkedin Email This piece appeared as an editorial opinion in the print edition of The Times of India.
Time of India
8 hours ago
- Time of India
Tripura CM mulls sex education in Class VIII-XII curriculum
Agartala: Tripura CM on Friday said the state govt is considering the introduction of sex education in the curriculum for students in Classes VIII to XII. Speaking at the legislative forum in the state assembly, Saha emphasised the importance of this initiative, stating, "We are considering incorporating sex education and HIV/AIDS awareness in the school curriculum in Class VIII-XII. Tired of too many ads? go ad free now This is not a matter of controversy, it is a necessity." He also encouraged community involvement, suggesting that MLAs could allocate funds to support HIV/AIDS patients. Saha highlighted the equal impact of HIV/AIDS on both boys and girls and stressed the importance of engaging youth in sports, cultural activities, and other creative pursuits to steer them away from drug addiction and reduce their vulnerability to HIV/AIDS. He said Tripura was the first state in India to introduce Red Ribbon Clubs in schools and plans to create youth ambassadors to lead campaigns against drug abuse. Expressing concern over the rising number of HIV/AIDS cases and injecting drug users, particularly among teenagers, Saha said an average of 120 new HIV infections are reported each month in the state, despite preventive efforts by the state AIDS Control Society. In response to a proposal by Congress legislator Sudip Roybarman, the chief minister supported the idea of adding a dedicated chapter on sex education and HIV/AIDS to the school curriculum to raise awareness among the most vulnerable age group. Additionally, he suggested that each MLA could allocate Rs 1 lakh per year from their area development fund for initiatives against drugs and HIV.
